On Tuesday, Cardiff Oncology Inc (NASDAQ: CRDF) was -5.35% drop from the session before settling in for the closing price of $2.43. A 52-week range for CRDF has been $2.09 – $5.64.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 19.36%. When this article was written, the company’s average yearly earnings per share was at 12.11%. With a float of $61.07 million, this company’s outstanding shares have now reached $66.53 million.
The extent of productivity of a business whose workforce counts for 33 workers is very important to gauge. In terms of profitability, gross margin is 77.41%, operating margin of -12784.0%, and the pretax margin is -12007.29%.
Cardiff Oncology Inc (CRDF) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Cardiff Oncology Inc stocks. The insider ownership of Cardiff Oncology Inc is 8.19%, while institutional ownership is 37.77%. The most recent insider transaction that took place on Jul 30 ’25, was worth 673,750. In this transaction Director of this company bought 275,000 shares at a rate of $2.45, taking the stock ownership to the 1,330,676 shares. Before that another transaction happened on Jul 30 ’25, when Company’s Director bought 15,000 for $2.45, making the entire transaction worth $36,750. This insider now owns 1,345,676 shares in total.
Cardiff Oncology Inc (CRDF) Latest Financial update
Going through the last 3-months fiscal report unveiled on the 9/30/2024, it has been observed that the corporation posted -0.25 earnings per share (EPS) during the time that was better than consensus figure (set at -0.27) by 0.02. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.22 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 12.11% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -4.08% during the next five years compared to 19.36% growth over the previous five years of trading.
Cardiff Oncology Inc (NASDAQ: CRDF) Trading Performance Indicators
You can see what Cardiff Oncology Inc (CRDF) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 4.42. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 278.20.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.88, a number that is poised to hit -0.20 in the next quarter and is forecasted to reach -0.87 in one year’s time.
Technical Analysis of Cardiff Oncology Inc (CRDF)
The latest stats from [Cardiff Oncology Inc, CRDF] show that its last 5-days average volume of 1.21 million was inferior to 1.44 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 34.64%.
During the past 100 days, Cardiff Oncology Inc’s (CRDF) raw stochastic average was set at 0.66%, which indicates a significant decrease from 2.97% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.16 in the past 14 days, which was lower than the 0.24 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.36, while its 200-day Moving Average is $3.43. Now, the first resistance to watch is $2.40. This is followed by the second major resistance level at $2.50. The third major resistance level sits at $2.55. If the price goes on to break the first support level at $2.24, it is likely to go to the next support level at $2.19. The third support level lies at $2.09 if the price breaches the second support level.
Cardiff Oncology Inc (NASDAQ: CRDF) Key Stats
There are 66,526K outstanding shares of the company, which has a market capitalization of 153.01 million. As of now, sales total 680 K while income totals -45,430 K. Its latest quarter income was 120 K while its last quarter net income were -13,940 K.
